This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

SciClone Pharmaceuticals (Holdings) Croissance future

Future contrôle des critères 3/6

SciClone Pharmaceuticals (Holdings) is forecast to grow earnings and revenue by 4.1% and 12.7% per annum respectively. EPS is expected to grow by 1.3% per annum. Return on equity is forecast to be 24.1% in 3 years.

Informations clés

4.1%

Taux de croissance des bénéfices

1.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	9.2%
Taux de croissance des recettes	12.7%
Rendement futur des capitaux propres	24.1%
Couverture par les analystes	Low
Dernière mise à jour	04 Jul 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02

Prévisions de croissance des bénéfices et des revenus

SEHK:6600 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	4,086	1,233	N/A	N/A	1
12/31/2024	3,583	1,120	N/A	1,057	2
12/31/2023	3,156	1,122	1,327	1,404	N/A
9/30/2023	3,017	1,038	1,185	1,322	N/A
6/30/2023	2,878	953	1,043	1,239	N/A
3/31/2023	2,814	904	1,015	1,211	N/A
12/31/2022	2,750	855	987	1,184	N/A
9/30/2022	2,706	844	1,107	1,214	N/A
6/30/2022	2,662	833	1,226	1,245	N/A
3/31/2022	2,590	878	1,032	1,137	N/A
12/31/2021	2,518	923	839	1,029	N/A
9/30/2021	2,259	837	506	840	N/A
6/30/2021	2,089	779	358	724	N/A
3/31/2021	2,004	766	435	853	N/A
12/31/2020	1,919	754	512	981	N/A
9/30/2020	2,001	817	657	974	N/A
12/31/2019	1,708	615	999	1,032	N/A
12/31/2018	1,409	535	143	167	N/A
12/31/2017	1,213	20	143	154	N/A
6/30/2017	1,166	294	N/A	242	N/A
3/31/2017	1,146	258	N/A	187	N/A
12/31/2016	1,112	213	N/A	240	N/A
9/30/2016	1,060	246	N/A	221	N/A
6/30/2016	1,072	257	N/A	231	N/A
3/31/2016	1,034	183	N/A	214	N/A
12/31/2015	1,021	191	N/A	211	N/A
9/30/2015	991	130	N/A	200	N/A
6/30/2015	913	102	N/A	210	N/A
3/31/2015	879	186	N/A	222	N/A
12/31/2014	836	156	N/A	171	N/A
9/30/2014	774	133	N/A	148	N/A
6/30/2014	790	140	N/A	173	N/A
3/31/2014	770	68	N/A	17	N/A
12/31/2013	769	66	N/A	58	N/A
9/30/2013	780	78	N/A	88	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 6600's forecast earnings growth (4.1% per year) is above the savings rate (2.2%).

Bénéfices vs marché: 6600's earnings (4.1% per year) are forecast to grow slower than the Hong Kong market (11.3% per year).

Croissance élevée des bénéfices: 6600's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 6600's revenue (12.7% per year) is forecast to grow faster than the Hong Kong market (7.6% per year).

Croissance élevée des revenus: 6600's revenue (12.7% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 6600's Return on Equity is forecast to be high in 3 years time (24.1%)

This company listing is no longer active

SciClone Pharmaceuticals (Holdings) Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

SciClone Pharmaceuticals (Holdings) Limited Announces Retirement of Wang Haixia as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings: EPS and revenues miss analyst expectations

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Investor sentiment deteriorated over the past week

Non-Executive Director Xiaozhuo Wang has left the company

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.13 in FY 2019)

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

SciClone Pharmaceuticals (Holdings) Limited has completed an IPO in the amount of HKD 2.180509 billion.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance